The muscle lost after a myocardial infarction is replaced with noncontractile scar tissue, often
initiating heart failure. Whole-organ cardiac transplantation is the only currently available …

During the last decade, embryonic stem cells (ESC) have unleashed new avenues in the
field of developmental biology and emerged as a potential tool to understand the molecular …

Background: In addition to scalability, human embryonic stem cells (hESCs) have the unique
advantage of allowing their directed differentiation toward lineage-specific cells. Objectives …

In recent years multiple reports indicating that embryonic as well as adult stem cells can
differentiate to cardiomyocytes have ignited discussions on whether these stem cells could …

Embryonic stem cell (ESC) lines, derived from the inner cell mass (ICM) of blastocyst-stage
embryos, are pluripotent and have a virtually unlimited capacity for selfrenewal and …

Background Adult clinical trials have reported safety and the therapeutic potential of stem
cells for cardiac disease. These observations have now translated to the pediatric arena. We …

Many forms of heart disease are associated with the loss of cardiomyocytes both via
apoptosis or necrosis, and despite the recent identification of resident cardiac stem cells, the …

Human embryonic stem cells (hESC s) can be differentiated into structurally and electrically
functional myocardial tissue and have the potential to regenerate large regions of infarcted …

This review highlights recent progress in the use of embryonic stem cell (ESC) systems for
studying and treating cardiovascular disease. Although ESCs represent an in vitro system …

We have demonstrated that human neonatal cardiosphere-derived cells (CDCs) derived
from the young are more regenerative due to their robust secretome. However, it is unclear …